trending Market Intelligence /marketintelligence/en/news-insights/trending/1LLELWSQuDhMZtmdST1z3Q2 content esgSubNav
In This List

Ardian to take control of Swiss drugmaker Sintetica

Podcast

Street Talk | Episode 94: Recessionary fears in '22 overblown, Fed could overtighten

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Ardian to take control of Swiss drugmaker Sintetica

Global private investment house Ardian agreed to acquire a majority stake in Swiss pharmaceutical company Sintetica SA Pharmaceuticals.

Sintetica's current stockholders will reinvest in the company and retain a minority stake.

Sintetica, which specializes in the research, manufacturing and marketing of anesthetics, analgesics, adrenergic agonists and other sterile injectable solutions, will pursue global expansion through the new partnership with Ardian.

Separately, an investor group including Ardian and Horizon Capital is selling British food and drink retailer EAT Ltd. to food shop operator Pret A Manger (Europe) Ltd.

Pret A Manger said in a release that it intends to convert most of EAT's shops to Veggie Prets to meet the rising consumer demand for more High Street vegetarian and vegan options.